T0	Outcomes 891 1081	included histologic assessment of bowel biopsies and assessment of serologic markers of inflammatory bowel disease (IBD), fecal calprotectin levels, and polymorphisms in immune-related genes
T1	Outcomes 1190 1274	levels to enteric flora, inflammatory cell infiltration into gastrointestinal mucosa
T2	Outcomes 1280 1366	increased fecal calprotectin associated with diarrhea and clinical evidence of colitis
T3	Outcomes 1562 1607	prevent ipilimumab-induced bowel inflammation
T4	Outcomes 1692 1700	diarrhea